ClinicalTrials.gg
CompletedNCT03424928Updated Feb 7, 2018

A Pilot Bioequivalence Study of Pomalidomide

A Phase 1 interventional study of Pomalidomide 4 MG Oral Capsule and Pomalidomide 4 MG Oral Capsule-Pomalyst in Bioequivalence, sponsored by Jiangsu Simcere Pharmaceutical Co., Ltd.. Completed at 1 site in China. Open to male participants aged 18 Years to 50 Years, including healthy volunteers. Per ClinicalTrials.gov, last updated 2018-02-07.

Sponsored by Jiangsu Simcere Pharmaceutical Co., Ltd. (part of Simcere Pharmaceutical Group Limited) · Phase 1, Interventional, and Treatment

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Phase
Phase 1
Study type
Interventional
Enrollment
12
Allocation
Randomized
Ages
18 Years to 50 Years
Sex
Male
01

Where this study stands

Counted across the records on this site · 2026-11-16

Among 102 studies testing pomalidomide in Multiple Myeloma — 15 open to participants now, 39 under way, 9 of them phase 3. pomalidomide · Multiple Myeloma.

Enrollment
81st of 102
12 · median 50
Started
2018
with 5 others
Phase 1
6 of 102
none open now
Registered
43rd of 102
by date

Among the 102 studies testing pomalidomide in Multiple Myeloma, this one is the 81st largest by enrollment, is one of 6 that started in 2018, is one of 6 in phase 1, and was the 43rd registered.

Multiple Myeloma

3,763 studies on the registry are indexed under Multiple Myeloma; 770 are open to participants now.

Browse Multiple Myeloma studies →

Open to participants now

15 of the 102 studies testing pomalidomide in Multiple Myeloma are open now, in 12 countries. Recruiting first, the newest first:

10 more — sign in →

By country, each count listing its studies:

All 15 open studies →

About pomalidomide

pomalidomide: first FDA approval 2013 (POMALYST), first EMA approval 2013. What it is approved for, and how studies give it, is on its page →

Who these studies take

Of the 585 Multiple Myeloma studies recruiting now, 430 (74%) set no upper age limit and 106 (18%) stop at 75 or younger; 36 take children under 18; 24 take healthy volunteers.

This study: 18 Years to 50 Years · male · healthy volunteers too.

The full table on the hub →

This tab as a report to print or save as PDF → With an account.

Was this useful?
Get alerts for this landscapeDownload CSVNarrow it in search →With an account: a weekly mail of what changed among 102 studies testing pomalidomide in Multiple Myeloma, or all of them as a file.
02

Study summary

Pomalidomide capsule were developed to offer an alternative to the marketed formulation, This pilot study was aim to pre-assess the bioequivalence of the capsule formulations under fasted condition.

03

Conditions studied

  • Bioequivalence

Browse trials for

Keywords

  • Pomalidomide
  • Multiple myeloma
  • Bioequivalence
04

Who can participate

Ages eligible
18 Years to 50 Years
Sexes eligible
Male
Accepts healthy volunteers
Yes

Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.

Inclusion criteria

  • Subjects should read, sign and date an Form and be fully informed of possible adverse events prior to any study procedures.
  • Subjects should complete the trial according to the regulations.
  • Subjects must agree to take effective methods to prevent pregnancy from 2 weeks before screening until 3 months of last dose administration. Subjects must agree to avoid semen and blood donation until 3 months of last dose administration.
  • Healthy male volunteers of 18-50 years old.
  • (BMI) ranges from 18.0 to 28.0 kg/m2, body weight ≥ 50 kg.
  • Medically healthy subjects with clinically normal Neutrophils and within 14 days.
  • No history of heart, liver, kidney, gastrointestinal tract diseases, nervous system, neural abnormities or metabolic abnormalities.

Exclusion criteria

Exclusion Criteria:

  • Smokers (>3 cigarettes/day)
  • History of allergic reactions to pomalidomide or Thalidomide analogues. Any food allergies, which in the opinion of the medical sub-investigator, contraindicates the subject's participation in this study.
  • Any history of thrombus or liver, kidney diseases.
  • History of Alcohol abuse (3990 ml beer, 1400 ml wine, 350 ml spirits/week)
  • Recent donation of plasma or significant loss of whole blood (>400 ml) within 3 months.
  • Subjects have difficulty to swallow or any clinical significant history of ongoing gastrointestinal problems which affect absorption of drugs.
  • Received a prescription medicine within 2 weeks prior to study dosing.
  • Received a non-prescription drugs, traditional Chinese medicine, health products within prior to study dosing.
  • Received a special food (dragon fruit, grapefruit or other tropical fruit) or strenuous exercise within 1 week prior to study dosing. Regular use of any drugs known to induce or inhibit hepatic drug metabolism within 30 days prior to study administration.
  • Any anticipation in other trial within 3 months.
  • Abnormal laboratory tests judged .
  • Positive test result for , HBeAg, HBeAb, HBcAB, HCvAB, antibody, Syphilis screening antibody.
  • Received a caffeine/Xanthine beverages or food within 48 h prior to study dosing.
  • Received an alcohol within 24 h prior to study dosing or positive test result for alcohol screening.
  • Positive test result for drugs of abuse.
  • Other reasons which, in the opinion of the medical sub-investigator, would prevent the subject from participating in the study.
Terms in these criteria, in plain language(7)

Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.

Informed consent

Before you join, the study team explains what taking part involves — its purpose, what happens, the risks and possible benefits — and answers your questions, so you can decide freely. Consent is usually recorded on a form (the informed consent form, ICF) signed by you or, where the law allows, by someone legally authorized to decide for you.

You can keep asking questions during the study, you are told of new information that matters, and you can choose to leave at any time.

Contraception

Ways of preventing pregnancy. “Highly effective” methods fail less than 1% of the time a year when used correctly — for example an IUD or an implant.

Criteria usually say which methods count and how long to keep using them after the last dose, sometimes for male participants too. Some studies accept a partner’s vasectomy if it was confirmed successful and that person is the participant’s only sexual partner.

BMI (body mass index)

Weight in kilograms divided by height in metres squared. Example: 70 kg and 1.75 m gives 70 ÷ (1.75 × 1.75) ≈ 22.9.

What counts as overweight or obesity differs between countries (some use lower cut-offs), so go by the range the study states.

Platelets

Blood cells that help blood clot. Too few raises the risk of bleeding and bruising. A usual adult range is about 150–400 × 10⁹/L (150,000–400,000 per µL); each lab has its own reference range.

Clinically significant

Judged by the study doctor to matter for your health or for the study. It is a doctor’s decision, so ask the study team if you are unsure whether something counts.

Hepatitis B tests

Hepatitis B is a virus that infects the liver. These are separate tests: HBsAg positive usually means a current infection (a recent vaccination can briefly cause it too); total anti-HBc (HBcAb) positive means an infection now or in the past; HBV DNA measures how much virus is in the blood.

Some studies accept a past infection if HBV DNA is undetectable, sometimes with antiviral medicine during the study. Check what this study allows.

HIV

The human immunodeficiency virus, which weakens the immune system.

Many studies now accept people whose HIV is controlled on treatment, judged by the viral load and the CD4 count. Check the limits this study sets.

05

Study design

Phase
Phase 1
Primary purpose
Treatment
Allocation
Randomized
Intervention model
Crossover assignment
Masking
None (open label)
Enrollment
12 participants (actual)

Study arms

  • Experimental
    Pomalidomide 4 MG Oral Capsule

    per os,capsule,4mg,1 capsule per period

    Drug: Pomalidomide 4 MG Oral Capsule

  • Experimental
    Pomalidomide 4 MG Oral Capsule-Pomalyst

    per os,capsule,4mg,1 capsule per period

    Drug: Pomalidomide 4 MG Oral Capsule-Pomalyst

Interventions

06

What researchers measure

Primary outcomes

  1. Peak Plasma Concentration (Cmax)

    90% CI of T/R within 80-125%

    Time frame: Day 1, Day 2, Day 3 of cycle 1, Day 8, Day 9, Day 10 of cycle 2.

  2. Area under the plasma concentration versus time curve from 0 to the last measurable concentration (AUC0-t)

    90% CI of T/R within 80-125%

    Time frame: Day 1, Day 2, Day 3 of cycle 1, Day 8, Day 9, Day 10 of cycle 2.

  3. Area under the plasma concentration versus time curve from 0 to infinity (AUC0-inf)

    90% CI of T/R within 80-125%

    Time frame: Day 1, Day 2, Day 3 of cycle 1, Day 8, Day 9, Day 10 of cycle 2.

07

Study locations

1 site
  • The second hospital of shanxi medical university
    Taiyuan, Shanxi 030001, China
08

Timeline

Tracking since Sep 25, 2026
ElapsedEstimatedEstimated, not yet reachedSimilar studies: half by the dot; the band is the middle halfHalf of similar studies reached it by the dot; the band is the middle half, from a quarter to three quarters

Ran from Jan 2018 to primary completion in Jan 2018, 0 months.

Of 212 industry-sponsored phase 1 interventional studies under Multiple Myeloma, half reached primary completion within 43 months of starting (the median), counting those still running; a quarter within 27 and three quarters within 71. This study's 0 months is below that.

Counting every sponsor, half of 413 studies reached it within 50 months; a quarter within 33 and three quarters within 75.

How these figures are worked out, and which studies are left out of them.

Registered
Dec 14, 2017
First posted
Feb 7, 2018
StartActual
Jan 19, 2018
Primary completionActual
Jan 29, 2018
CompletionActual
Feb 6, 2018
Last update
Feb 7, 2018
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
No changes since tracking began. The registry record was last updated on Feb 7, 2018, before this site started recording changes on Sep 25, 2026. Its history is on ClinicalTrials.gov ↗
09

Registry details

Key details

Study ID
NCT03424928
Collaborators
Second Hospital of Shanxi Medical University
Responsible party
Sponsor
First posted
Feb 7, 2018
Start date
Jan 19, 2018
Primary completion
Jan 29, 2018
Completion
Feb 6, 2018
Last update
Feb 7, 2018

Study contacts

Ruigang Hou, Bachelor
principal investigator · Second Hospital of Shanxi Medical University
Linhua Linhua, PhD
principal investigator · Second Hospital of Shanxi Medical University

Oversight

Data monitoring committee
No
FDA-regulated drug
No
FDA-regulated device
No
View the source record on ClinicalTrials.gov ↗

Not currently enrolling

This study is completed, as verified in Feb 2018. You cannot join it, but the record below documents what was studied.

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Studies of the drug tested here: Pomalidomide

Start the discussion